
    
      The study aims to evaluate the safety, pharmacokinetics and to determine the potential dose
      limiting toxicity of HHT201 in healthy subjects between the ages of 20-59, 6 in 17mg dose
      group and 20 in 34mg dose group. Another 12 subjects will be administered a tablet of 5mg
      Donepezil Hydrochloride to get the PK profile of Donepezil as reference. Eligible subjects
      will be accepted into the protocol after review and providing voluntary written informed
      consent forms and completion of a comprehensive medical, physical examination, and routine
      laboratory assessment.
    
  